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ABSTRACT
Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from
the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally
related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low risk types 6 and 11,
causing genital warts.
Objective: To estimate the lifetime risk (up to the age of 75 years) for developing cervical cancer after
vaccinating a HPV na€ıve girl (e.g. 9 to 12 years old) with the 9vHPV vaccine in the hypothetical absence of
cervical cancer screening.
Methods: We built Monte Carlo simulation models using historical pre-screening age-speciﬁc cancer
incidence data and current mortality data from Denmark, Finland, Norway, Sweden and the UK. Estimates
of genotype contribution fractions and vaccine efﬁcacy were used to estimate the residual lifetime risk
after vaccination assuming lifelong protection.
Results: We estimated that, in the hypothetical absence of cervical screening and assuming lifelong
protection, 9vHPV vaccination reduced the lifetime cervical cancer and mortality risks 7-fold with a
residual lifetime cancer risks ranging from 1/572 (UK) to 1/238 (Denmark) and mortality risks ranging from
1/1488 (UK) to 1/851 (Denmark). After decades of repetitive cervical screenings, the lifetime cervical
cancer and mortality risks was reduced between 2- and 4-fold depending on the country.
Conclusion: Our simulations demonstrate how evidence can be generated to support decision-making by
individual healthcare seekers regarding cervical cancer prevention.
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recombinant vaccine
nonavalent; Types 6, 11, 16,
18, 31, 33, 45, 52, 58,
modelling
Introduction
Human papillomavirus (HPV) is the most common viral infec-
tion of the reproductive tract. It is sexually transmitted and
ubiquitous – most sexually active women will be infected at
some point in their lives and some may be repeatedly infected.1
Worldwide point prevalence is estimated at 10.4%.2 Cervical
cancer is caused by persistent infection with high-risk HPV3
and is the fourth most common cancer in women worldwide
and the second most common cancer in women 25–40 years.4
Cervical cancers are largely preventable; primary prevention of
infection through vaccination and secondary prevention to detect
and treat pre-cancerous cervical lesions through screening.
Screening impacts upon cervical cancer incidence only with no
effect on the prevalence of HPV infection in the population,
whereas vaccination prevents HPV infection and all stages of cer-
vical cancer disease, from cervical pre-cancerous to invasive dis-
ease.5 Vaccination also prevents the non-cervical HPV cancers.
The nonavalent HPV (9vHPV) vaccine (Gardasil9 , Merck/
MSD), approved in Europe since June 2015,6 covers the seven
most common oncogenic HPV types (16/18/31/33/45/52/58)
associated with cervical cancer, in addition to low-risk types 6
and 11 which are responsible for 90% of genital warts.7 The
9vHPV efﬁcacy was 97.1% [95% CI: 83.5%–99.9%] against
high-grade cervical disease related to HPV-31, 33, 42, 52 and
58, based on clinical endpoints (disease, biopsy proved). The
9vHPV efﬁcacy was similar to that of the quadrivalent HPV
(4vHPV) vaccine against disease related to HPV-6, 11, 16 and
18, based on non-inferior immune response,8,9 with the 4vHPV
CONTACT Kaatje Bollaerts Kaatje.Bollaerts@p-95.com Vlierbeeklaan 18, 3010 Kessel-lo, Belgium.
Supplemental data for this article can be accessed on the publisher’s website.
Source of support: Academic authors did not receive any honoraria for the work reported here. MSD covers the costs associated with the development and publication of
this manuscript through contract with P95.
© 2018 Karl-Ulrich Petry, Kaatje Bollaerts, Paolo Bonanni, Margaret Stanley, Rosybel Drury, Elmar Joura, Susanne K. Kjaer, Chris J. L. M. Meijer, Didier Riethmuller, Benoit Soubeyrand, Pierre Van
Damme, and Xavier Bosch. Published with license by Taylor & Francis
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2018, VOL. 14, NO. 7, 1800–1806
https://doi.org/10.1080/21645515.2018.1450125
efﬁcacy being estimated to be 98.2% [95% CI: 93.5%–99.8%]
against high-grade cervical disease related to HPV-16 and 18.6
Among all vaccinations, HPV vaccination is the only vacci-
nation implemented in a context where secondary prevention
(cervical screening) is already in place. For at least 50 years, the
main cervical cancer control measure has been secondary pre-
vention through screening. Scandinavian countries were
the earliest adopters of population-based screening in the
1960s.10-12 In countries where organized cytological screening
programmes are available, the incidence of squamous cell carci-
noma of the cervix has declined.13,14 In some countries, cervical
cancer screening programmes have recently shifted towards
HPV DNA testing which is more sensitive, although less spe-
ciﬁc than cytology.15
A vast body of literature is available on modelling the impact
of screening and HPV immunization programmes on the
HPV-related cancer burden at population level, accounting for
both direct and indirect protection (i.e. indirect protection of
non-immunized by immunized).16,17 Modelling studies focus-
ing on the individual-level beneﬁts of HPV vaccination are, to
our knowledge, non-existing despite the value of such studies
to inform decision-making by individual healthcare seekers.
This study aims to demonstrate how evidence can be gener-
ated to support decision-making by individual healthcare
seekers regarding cervical cancer prevention. To this end, we
estimated the lifetime risks for developing cervical cancer (or
the probability that an individual will develop the disease dur-
ing a certain age span in the absence of competing causes of
death) in vaccinated and unvaccinated females in a number of
European countries as well as the corresponding lifetime mor-
tality risks. Particularly, we estimated the current lifetime risk
(up to the age of 75 years) of cervical cancer and related mortal-
ity in (i) the hypothetical absence of any HPV prevention mea-
sure and in (ii) the case of 9vHPV vaccination of HPV na€ıve
girls assuming lifelong protection (assuming booster doses will
be used if required). Lifetime risks were estimated for European
countries with publicly available pre-screening cancer incidence
data (e.g. Denmark, Finland, Norway, Sweden and the UK). We
compared these estimates with the risk reductions observed
after decades of repetitive screening in countries with a high
uptake of cervical cancer screening. To facilitate the communi-
cation to individual healthcare seekers, we visually present the
lifetime risks.
Results
In the hypothetical scenario of no HPV prevention measures,
cervical cancer lifetime risk (1/N) ranged from 1/76 (UK) to 1/
31 (Denmark) and the lifetime mortality risk from cervical can-
cer (1/N) ranged from 1/205 (UK) to 1/117 (Denmark)
(Figure 1, see also Appendix A for table with lifetime risk esti-
mates and 95% uncertainty intervals). Vaccination with
9vHPV, assuming lifelong protection, and in absence of addi-
tional prevention measures was estimated to reduce the lifetime
cervical cancer risks to values ranging from 1/548 (UK) to 1/
228 (Denmark) and the related lifetime mortality risk to values
ranging from 1/1488 (UK) to 1/851 (Denmark). Overall, vacci-
nation decreased the lifetime cervical cancer and related mor-
tality risk by approximately 7-fold. The lifetime cervical cancer
and the related mortality risks observed after decades of repeti-
tive cervical screening decreased 2- to 4-fold, depending on the
country (Figure 1, Appendix A).
The sensitivity analyses (Table 1) showed that the cervical
cancer incidences based on the (country-independent) natural
history model (42.5/100.000) fell in between the lowest (23.9/
100.000) and the highest country-speciﬁc incidences (71.6/
100.000) calculated based on the historical pre-screening data.
The cervical cancer incidences derived from the CIN3 data
were lower than the ones based on the historical data, likely
explained by the impact of screening on the current CIN3 inci-
dences. The cervical cancer incidences derived from Age-
Period-Cohort (APC) models were comparable to the ones
based on the historical data, implying that the estimated cohort
effects were small.
Discussion
This simulation study provides cervical cancer and related
mortality lifetime risk estimates in the absence of any HPV
prevention measures (i.e. in absence of both screening and
Figure 1. Lifetime risk (up to the age of 75) of cervical cancer (left) and related mortality (right) in the scenarios of either: no HPV prevention measures, after 9vHPV vacci-
nation in the hypothetical absence of cervical cancer screening and after cervical cancer screening. The error bars reﬂect 95% uncertainty intervals. Risks are expressed as
1/N.
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vaccination) and after 9vHPV vaccination in the absence of
screening. To our knowledge, this is the ﬁrst modelling study
on cervical cancer prevention from the perspective of the indi-
vidual healthcare seeker as opposed to studies modelling the
impact of HPV screening and immunization programmes on
the disease burden at population level.16,17 Through Monte
Carlo simulation, we estimated that the lifetime cervical cancer
and related mortality risks reduced 7-fold after vaccination
compared to 2- to 4-fold after decades of repetitive screening, a
reduction that has not changed for several years. Although inci-
dences were only obtained for ﬁve countries, we consider the
ﬁndings regarding the lifetime risk reductions after vaccination
generalizable to other geographical areas with comparable
HPV infection incidence and genotype attributions.
For the conduct of this simulation study, we made several
assumptions. First, we assumed lifelong vaccine protection.
Although currently there is no evidence of waning immunity
even 12 years after vaccination,18 we assume that booster
doses will be given to acquire lifelong protection if needed.
Second, we focused on direct protection against vaccine-
type HPV and do not account for herd protection or cross-
protection as we deem the direct effects to be of the highest
relevance for the perspective of the individual healthcare
seeker. Third, we did not use historical mortality data to cal-
culate the mortality risk in the hypothetical absence of
screening as treatment for cervical cancer has substantially
improved over the years.19 Instead, we derived the mortality
ratio using current (year 2012) cervical cancer incidence
and mortality data, and applied this ratio to historical pre-
screening cervical cancer incidences. This approach may
have underestimated the mortality risk: without screening,
cancers not prevented by the vaccine will be detected later
and their treatment might be less successful, leading to
more deaths. Fourth, screening practices and screening
adherence are continuously evolving over time, implying
that the future residual cervical cancer and -mortality risks
after screening will be different from the currently estimated
residual risks after screening. Fifth, the screening estimates
refer to population-average screening as it is unknown
whether the girl eligible for vaccination will comply with the
screening recommendations when grown up. This popula-
tion-averaged risk reduction is smaller than the risk reduc-
tion for a person fully compliant with the screening
recommendations. Nevertheless, the population-averaged
lifetime risk estimates after screening might provide a useful
benchmark for the lifetime risks after vaccination. Sixth, his-
torical pre-screening cervical cancer incidence data do not
necessarily reﬂect what would have been the current HPV
epidemiology in the hypothetical absence of screening.
Indeed, indirect evidence suggests that HPV infection has
become more prevalent over the last 50 years, mainly due to
changes in sexual behaviour.20,21 This implies that the use of
historical data would underestimate the current cervical can-
cer risk in the hypothetical absence of screening. We there-
fore conducted three sensitivity analyses using (i) a natural
history model, (ii) current CIN3 incidences and (iii) results
from APC models. The results of the sensitivity analyses
were in line with the results based on the historical pre-
screening incidence data, and therefore we opted for the lat-
ter approach for reasons of simplicity. Finally, we did not
calculate the residual risk of the combined prevention strat-
egy of vaccination and screening as it is unknown whether,
at the time when the girl (and her parents/guardians) needs
to take the decision to get vaccinated (i.e. around the age of
the 10 years), the girl will adhere to the screening recom-
mendations. In either case, the residual risk of the combined
strategy will be less than the residual risk after vaccination
or screening alone.
Despite these limitations, we believe that our simulations
demonstrate how evidence can be generated to support
decision-making regarding cervical cancer prevention by
individual healthcare seekers (in this case, adolescent girls).
Concepts like vaccine effectiveness and genotype attribution
are difﬁcult to explain to healthcare seekers. By translating
these into individual lifetime risks, more tangible, easier to
understand ﬁgures are obtained. The clarity of such ﬁgures
can be further improved by means of visual aids, such as
the Paling palette, designed to facilitate the communication
of probabilities.22 Figure 2 illustrates how a Paling palette
could be used to communicate lifetime risk estimates with-
out any prevention, after vaccination and after screening.
We hope that our simulations demonstrated how the bene-
ﬁts of cervical cancer prevention strategies can be commu-
nicated to advising clinicians and healthcare seekers, with
the objective of supporting decision-making and encourag-
ing compliance to prevention measures. In this work, we
focussed on the life-time risk of cervical cancer and related
mortality after 9vHPV vaccination despite that the 9vHPV
vaccine also prevents other HPV-related diseases, including
anal, vaginal and vulvar cancer as per indication.6 The same
approach can be used to quantify the residual life-time risks
after vaccination of these other HPV diseases and to quan-
tify the risk of adverse events. To fully inform a healthcare
seeker, additional analyses addressing all the beneﬁts and
risks of both vaccination and screening are needed.
Table 1. Cervical cancer incidence (/100.000) in the hypothetical absence of any
HPV prevention measure and residual incidence in the case of 9vHPV vaccination
of HPV na€ıve girls, in the hypothetical absence of HPV screening and assuming life-
long protection. Base-case results and results from thee different sensitivity
analyses.
Cervical cancer incidence (/100.000)
Medium [95% uncertainty intervals]
Approach Age No prevention After vaccination
Base case: pre-screening data
Denmark 30–60 71.62 [66.18;77.34] 9.47 [7.16;13.2]
Finland 30–60 31.68 [28.04;35.62] 4.19 [3.12;5.91]
Norway 30–60 35.07 [30.88;39.62] 4.64 [3.45;6.54]
Sweden 30–60 39.59 [36.53;42.83] 5.24 [3.96;7.3]
UK 30–60 23.92 [22.91;24.96] 3.16 [2.41;4.38]
Sensitivity: natural history model
30–60 42.47 [37.16;47.78] 5.85 [4.37;7.72]
Sensitivity: CIN3
Sweden 30–60 21.65 [11.48;37.39] 2.98 [1.51;5.45]
UK 30–60 22.87 [13.57;35.83] 3.15 [1.77;5.28]
Sensitivity: Age-Period-Cohort (APC)
Denmark 30–74 76.07 [70.7;81.55] 10.49 [7.98;13.62]
Finland 30–74 22.82 [20.16;25.78] 3.14 [2.35;4.18]
Norway 30–74 44.82 [40.62;49.38] 6.18 [4.67;8.1]
Sweden 30–74 36.88 [33.85;40.1] 5.09 [3.86;6.64]
Denmark 30–74 76.07 [70.7;81.55] 10.49 [7.98;13.62]
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Materials and methods
Lifetime- and residual lifetime risk
We used lifetime risk to express the risk of disease and related
mortality from the perspective of the individual healthcare
seeker. If the lifetime risk is less than 10%, it is well approxi-
mated by the cumulative rate or the summation of the age-spe-
ciﬁc incidence rates over each year of age from birth to a deﬁned
upper limit.23 Speciﬁcally, the lifetime risk of cervical cancer in
absence of any HPV prevention measure was calculated as
riskNO PREV  cum: rateD
XI
iD 1
wirno prev i; (1)
with rno prev iD di 6 yi being the annual age-speciﬁc cervical
cancer incidence or mortality rate in the absence of any HPV
prevention measure within the ith age group of width wi, and
where di is the number of cases and yi the number of person
years at risk within the ith age group. The standard error23 is
then calculated as
se cum:rateð ÞD
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXI
iD 1
di
wi
yi
 2
:
vuut (2)
Residual lifetime risk after vaccinating a HPV na€ıve girl with
the 9vHPV vaccine in the absence of other HPV prevention
measures was estimated as the lifetime risk without HPV pre-
vention multiplied with the fraction of the disease not prevent-
able through vaccination. Assuming lifelong protection, this
equals
res:riskVACC D
XI
iD 1
wirno prev i£ 1¡ k
X7
kD 1
gk VEk
" #
; (3)
with k being the HPV attributable fraction, gk the k
th geno-
type contribution and with VEk being the genotype-speciﬁc
Figure 2. Paling palette displaying the lifetime risk (per 1000 women) of developing cervical cancer by the age of 75 and after cervical screening (yellow), after 9vHPV
vaccination in the hypothetical absence of cervical cancer screening (green) and in the absence of HPV prevention (pink). The risks are calculated using the mid-values of
the range of the lifetime cervical cancer risks.
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vaccine efﬁcacy (where k refers to 1 of the 7 oncogenic geno-
types covered in 9vHPV vaccine). To obtain (residual) lifetime
mortality risk estimates, we multiplied the lifetime cervical
cancer risk with the corresponding mortality ratio λ. Finally,
to facilitate the communication of the results to individual
healthcare seekers, we presented lifetime and residual lifetime
risk measures as 1/X (i.e. 1 person out of the X persons will
develop the disease) and visually presented them using the
Paling palette, designed to facilitate the communication of
probabilities.22
Monte Carlo simulation and sources
We built Monte Carlo simulation models to obtain esti-
mates of the uncertainty in the (residual) lifetime risk esti-
mates, reﬂecting the uncertainty in the parameters used to
calculate these lifetime risks. An overview of the simulation
model and input parameters is provided in Table 2. For
every analysis, we generated 10.000 runs, based on which
we calculated the median residual lifetme risks and the 95%
uncertainty intervals (UI). All analyses were carried out in
R version 3.4.0.24 The sources of the input parameters are
described below.
Cancer and mortality incidences
Cervical cancer screening is widely implemented in the vast
majority of the European countries. To estimate the effect
of vaccination in the absence of screening, we searched for
publicly available European historical pre-screening cancer
incidence data. We obtained historical data for Denmark,
Finland, Norway, Sweden and the UK. Details on the coun-
tries’ HPV epidemiology and prevention policy are given in
Appendix B. For the UK, we obtained data from 1989,
immediately after the inception of the national screening
programme in 1988,25 whereas for the Scandinavian coun-
tries we obtained incidence data from 1960, well before the
start of organized screening in the mid-1960s.10-12 We did
not use historical cervical cancer related mortality data,
because of recent improvements in cancer treatment.
Instead, we calculated the mortality ratio by dividing the
number of cervical cancer related deaths by the number of
Table 2. Summary of the input parameters, distributions and sources.
Parameter Distribution Source
Cervical cancer incidence
Denmark inc » normal cr; se crð Þ
 
calculation cumulative rate (cr) as in
formula1 and2
NORDCAN* (yr 1960)25
Finland same same NORDCAN* (yr 1960)25
Norway same same NORDCAN* (yr 1960)25
Sweden same same NORDCAN* (yr 1960)25
UK same same Trent Cancer Registry* (yr
1989)26
HPV attribution (k D 99.7%)
Constant Walboomers3
Genotype attribution ( g1618D 72:8 % ; gaddD 16:2 %)
½p1618;padd;pother» n16181498 De Sanjose27
dirichlet n1618; nadd ; notherð ÞC 1 nadd333
( p D proportion of cancers attributable to types nother D 227
16–18, the additional types and other types) (n D number of cervical cancers with
genotypes 16–18, the additional
types and other types)
Vaccine effectiveness ( VE1618D 98:2% ; VEadd D 97:1%)
types16, 18 pt » beta st C 1;Nt ¡ st C 1ð Þ Nt D 8493, st D 2, Summary of Product
Characteristics Gardasil96Nc D 8464, sc D 112pc» beta scC 1;Nc¡ scC 1ð Þ
VE D 1¡ pt=pc
( p D disease probability in treatment and control group)
(N D population size, s D number of
events in treatment group t and
control group c)
Add types same Nt D 5949, st D 1 same
Nc D 5943, sc D 35
Mortality ratio (r)
Denmark r » pm
pca
N D 2823776, sca D 363, Eurostat28
pm» beta smC 1;N ¡ smC 1ð Þ IARC29
pca» beta scaC 1;N ¡ scaC 1ð Þ sm D 97 (yr 2012)
(N D population size,, sca D number of
cancer events, sm D number of
mortality events)
( p D cancer and mortality probability)
Finland same N D 2770906, sca D 143, sm D 5 same
Norway same N D 2540963, sca D 294, sm D 101 same
Sweden same N D 4830507, sca D 451, sm D 187 same
UK same N D 32481347, sca D 2659, sm D 979 same
NORDCAN, available from: http://www-dep.iarc.fr/nordcan.htm25
Trent Cancer Registry, available from: http://www.empho.org.uk/tcr/aboutUs.aspx
Eurostat, available from: http://ec.europa.eu/eurostat
IARC, available from: http://globocan.iarc.fr/Pages/age-speciﬁc_table_sel.aspx
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cervical cancer cases for 20124 and applied this ratio to the
historical cervical cancer incidence data (Table 2).
HPV attribution
Virtually all cervical cancers are caused by HPV.3
Genotype attribution
We obtained European genotype contribution data for the 7
oncogenic genotypes included in the 9vHPV vaccine.26 For cer-
vical cancer, HPV types 16–18 were detected in 71% of cases,
the 5 additional HPV types being detected in 16% of cases.26
Vaccine efﬁcacy (VE)
VE for CIN2C (proxy for cervical cancer) is 98.2% [95% CI:
93.5%–99.8%] for genotypes 16 and 18 and 97.1% [95%CI:
83.5%–99.9%] for the 5 additional high-risk types 31, 33, 45, 52
and 58.
Sensitivity analyses
The historical pre-screening cancer incidence data may not be
representative of the cervical cancer epidemiology that would
have been observed today in the hypothetical absence of screen-
ing. Hence, we conducted several sensitivity analyses, deriving
cervical cancer incidences from; (i) a natural history model,27
(ii) current pre-invasive lesion (CIN3) incidences28-31 multi-
plied with the cervical cancer progression risk32 and (iii) cancer
incidences derived from Age-Period-Cohort (APC) models
projecting the cervical cancer incidence that would have been
observed today in the absence of screening accounting for
cohort effects (such as changes in sexual attitude).33 As for
most of these approaches age-speciﬁc data were not available,
overall (residual) cervical cancer incidences (per 100.000) were
calculated instead of lifetime risks (details in Appendix C).
Cervical screening
To put the residual lifetime risk estimates after vaccination into
perspective, we also estimated the lifetime risk after cervical
screening or,
riskSCREEN D
XI
iD 1
wircurrent i; (4)
with rcurrent i being the current annual age-speciﬁc incidence or
mortality rate within the ith age group of width wi. Particularly,
we used the age-speciﬁc cervical cancer incidence and mortality
data from 2012,25,34 reﬂecting the impact of decades of screen-
ing.
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